HDAC9 and cancer: Novel strategies to limit or reverse multidrug resistance include miRNA, DNA methyltransferase inhibitors (DNMTis), hypomethylating agents (HMAs), and histone deacetylase inhibitors (HDACis) [24], but HDAC inhibitors elicit divergent responses in drug-sensitive and resistant cancer cells [25].